Good morning,
Pet owners may have a brain that is biologically up to 15 years “younger” than that of people without a pet. This is suggested by findings from the Alabama Brain Study on Risk for Dementia. The analysis indicates that regular contact with a four-legged companion may be associated with better performance in cognitive tests as well as greater volume in certain brain structures responsible for attention and memory. The strongest effect was observed among dog owners.
At Bioceltix, we are committed to ensuring the best possible quality of life for our four-legged companions. We are glad to see that everyone benefits! 🐾
We invite you to take a look at the most important news from the company:
- The Chief Pharmaceutical Inspector has granted Bioceltix a Good Manufacturing Practice (GMP) certificate in the pharmaceutical standard. This means that our facility meets GMP requirements for the manufacturing of sterile biological medicinal products in the field of cell therapies for animals. The certificate is a necessary requirement in the registration process with the European Medicines Agency (EMA). This is another step bringing us closer to introducing our therapies to the European market. | Read more
- After receiving the environmental decision from the Mayor of Wrocław, it is time for the next formal stage in the implementation of our investment – submitting an application for a building permit for the new manufacturing facility. In accordance with the procedure, the decision on the permit should be issued within 65 days from the date we submitted the documentation (we filed the application on March 6). – We have already announced the first tenders, and together with contracted subcontractors we are carrying out further stages of the work. We are at a very dynamic and exciting moment in the company’s development – comments Paweł Wielgus. | Read more
- Our efforts and breakthrough approach to animal treatment are being recognized by the market. We received Rekiny Biznesu Award 2026, taking 3rd place in the “Innovative Companies” category. In the competition organized by inwestycje.pl and inwestorzy.tv, candidates are first nominated by individual investors, and the final winners are selected by a panel of capital market experts. Thank you! | Read more
- London is calling 💂 The Animal Health, Nutrition & Technology Innovation conference has become a regular fixture in our calendar. As one of the most important discussion platforms dedicated to animal health, it brings together scientists, innovators, investors, and industry leaders. In this distinguished group, we had the opportunity to present our projects and research results. We also discussed them during one-on-one meetings in the dedicated Bioceltix zone. We returned from London convinced that our strategy and plans align perfectly with the needs of this rapidly growing market. We will also discuss the promising biotechnology sector during the upcoming Invest Cuffs conference in Kraków. What are the opportunities and challenges for biotech in Poland and worldwide? Which global trends will benefit Polish companies? The answers will come on March 20 at the ICE Kraków Congress Centre. The outlook for Bioceltix will be presented by Paweł Wielgus, PhD. | Read more
We are setting sail for international waters:
- Regenerative medicine is becoming increasingly prominent in the world of animal health. A report prepared by the American Animal Hospital Association and Gallant shows that as many as 95% of veterinarians expect cell therapies to be introduced into standard treatment practice within the next 10 years. Moreover, 79% of respondents declare their willingness to use such therapies in their practice in the future. The authors of the study emphasize that well-designed clinical trials, standardized manufacturing processes, and appropriate regulatory oversight are key to the sector’s development. This is precisely the direction in which veterinary biotechnology is evolving today. And us? We are consistently developing solutions in line with the highest standards expected by the industry. | Read more
- New analyses show how widespread—and often overlooked—osteoarthritis is in dogs. A study conducted by researchers from the University of Tennessee on a group of 30 medium- and large-breed dogs presented for routine dental examinations revealed radiological signs of the disease in 60% of the animals. The changes most frequently affected the joints of the pelvic limbs. The results confirm earlier reports: osteoarthritis may develop for a long time without clear clinical symptoms. This is another argument for early prevention, including routine veterinary procedures and the diagnosis of joint diseases in four-legged companions. | Read more
- The UK regulator, the Veterinary Medicines Directorate (VMD), has completed a safety review of Librela®—a monoclonal antibody used in the treatment of osteoarthritis in dogs. The analysis covered a range of adverse reactions reported in patients following administration of the drug. Reports included worsening joint conditions, cases of weakness, and even deaths of animals. The regulator concluded that the therapeutic benefits continue to outweigh the potential risks, although increased vigilance in monitoring patients was recommended. In January 2026, the product information was updated, expanding the list of possible adverse effects to include, among others, immune-mediated polyarthritis, paresis, and paralysis. To date, Zoetis has sold more than 21 million doses of the drug worldwide. | Read more
- Metabolic disorders can significantly influence the choice of treatment for joint diseases in sport horses. Increasing evidence indicates that corticosteroid injections raise insulin and glucose levels, increasing the risk of laminitis (a painful hoof disease) in animals with metabolic disorders. As a result, veterinarians are increasingly considering alternative treatment methods, such as hyaluronic acid, hydrogels, or stem cell–based products. In this context, the importance of innovative therapies is growing, along with the potential of our BCX-EM—a product for joint inflammation in horses based on allogeneic mesenchymal stem cells. | Read more
- The number of cats in our homes is steadily increasing—and fortunately, they are living longer. Growing interest in the cat segment is being observed not only among pet owners but also industry leaders. We ourselves have long held ambitious plans for this segment. Virbac has just expanded its portfolio of companion animal medicines by acquiring the product Thyronorm from Norbrook, used to treat feline hyperthyroidism. The £100 million transaction gives the company full commercial rights to a product widely used in the treatment of one of the most common endocrine disorders in older cats. Virbac expects the acquisition to drive sales growth and improve EBITDA margins from the first year. | Read more
We share even more industry updates and the latest news on our progress on LinkedIn—follow Bioceltix on social media and our website.
If you have suggestions regarding the newsletter content, we encourage you to get in touch at: newsletter@bioceltix.com.
Best regards,
The Bioceltix Team